Scientists Find New Marker that Predicts Early Breast Cancer Recurrence
Scientists found a marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
Scientists found a marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
MicroRNA (miRNA) can be used as a biomarker to predict which patients are likely to face breast cancer recurrence and mortality.
Black and Asian women are more likely to experience delays in getting breast biopsies after a mammogram identifies an abnormality.
New research has found a connection between aggressive breast cancer cells and the dual CXCR4-CCR7 cell surface protein complexes.
Read MoreUsing current standard HER2 assays as a diagnostic test may result in a mis-assignment for treatment of breast cancer with a promising new drug.
Read MoreThe partnership is intended to advance the use of next-generation sequencing (NGS) for decentralized oncology testing.
Read MoreBioReference will use Gestalt Diagnostic’s Digital Pathology solution with Mindpeak’s AI cancer diagnostics algorithm for quantification of cancer cells.
Read MoreThe novel metastatic breast cancer test includes both cell-based and cell-free analysis from a single blood draw.
Read MoreA new assay can identify HER2 and other tumor alterations in the cerebrospinal fluid of patients with breast cancer and leptomeningeal disease (LMD).
Read MoreRoche will launch three new automated digital pathology algorithms, that will serve as important biomarkers for breast cancer patients.
Read MoreThe safe, painless diagnostic tool used to detect breast cancer uses a low electrical current instead of radiation.
Read MoreThe US Food and Drug Administration (FDA) has granted ‘Breakthrough Device Designation’ for Datar Cancer Genetics’ ‘TriNetra’ blood test for breast cancer.
Read MorePhysicians are less likely to refer Black women with breast cancer for genetic counseling and testing services.
Read MoreQuest Diagnostics will provide clinical laboratory testing using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) immunohistochemistry companion diagnostic.
Read MoreRoche has entered an agreement with Ibex Medical Analytics, a provider of artificial intelligence (AI)-based cancer diagnostics.
Read MoreResearchers in Sweden have developed a new artificial intelligence analyzer that may help predict breast cancer.
Read MoreUndergoing genetic testing Keri Forsythe-Stephens, learned she had a mutation of the gene, CHEK2, making her more susceptible to breast cancer.
Read MoreOneOncology and Genentech presented data at a symposium that examined genomic profiling and biomarker testing patterns in community oncology centers.
Read More